[{"id":"f7a6174e-7fc7-43b8-86df-9aff3711091d","acronym":"EMR 63325-015","url":"https://clinicaltrials.gov/study/NCT01496131","created_at":"2021-01-18T06:16:08.326Z","updated_at":"2024-07-02T16:37:13.158Z","phase":"Phase 2","brief_title":"Tecemotide (L-BLP25) in Prostate Cancer","source_id_and_acronym":"NCT01496131 - EMR 63325-015","lead_sponsor":"EMD Serono","biomarkers":" MUC1","pipe":"","alterations":" ","tags":["MUC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • goserelin acetate • Stimuvax (tecemotide) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 10/24/2011","start_date":" 10/24/2011","primary_txt":" Primary completion: 11/25/2016","primary_completion_date":" 11/25/2016","study_txt":" Completion: 11/25/2016","study_completion_date":" 11/25/2016","last_update_posted":"2018-03-09"},{"id":"7c6bfff4-5011-444a-90d9-1ef097eadebd","acronym":"","url":"https://clinicaltrials.gov/study/NCT01462513","created_at":"2021-01-18T06:05:01.468Z","updated_at":"2024-07-02T16:37:13.981Z","phase":"Phase 2","brief_title":"L-BLP25 in Patients With Colorectal Carcinoma After Curative Resection of Hepatic Metastases","source_id_and_acronym":"NCT01462513","lead_sponsor":"Prof. Dr. Carl Schimanski","biomarkers":" MUC1","pipe":"","alterations":" ","tags":["MUC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Stimuvax (tecemotide)"],"overall_status":"Completed","enrollment":" Enrollment 122","initiation":"Initiation: 08/01/2011","start_date":" 08/01/2011","primary_txt":" Primary completion: 12/31/2017","primary_completion_date":" 12/31/2017","study_txt":" Completion: 01/31/2018","study_completion_date":" 01/31/2018","last_update_posted":"2018-02-13"},{"id":"f3810cf4-5645-4a8e-aaa3-0c8ad990325f","acronym":"FINGERPRINT","url":"https://clinicaltrials.gov/study/NCT01731587","created_at":"2021-01-18T07:34:17.378Z","updated_at":"2025-02-25T14:49:39.621Z","phase":"Phase 1","brief_title":"Anti-cancer MUC1-specific Immunotherapy for Unresectable Stage III Non-small Cell Lung Cancer","source_id_and_acronym":"NCT01731587 - FINGERPRINT","lead_sponsor":"Merck KGaA, Darmstadt, Germany","biomarkers":" TGFB1 • IFNA1 • CRP","pipe":"","alterations":" ","tags":["TGFB1 • IFNA1 • CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Stimuvax (tecemotide) • cyclophosphamide intravenous"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 01/01/2001","start_date":" 01/01/2001","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2017-02-28"},{"id":"50680306-c8c0-4e02-9bf0-71ac36cdd8cd","acronym":"SPRINT","url":"https://clinicaltrials.gov/study/NCT01507103","created_at":"2021-01-18T06:19:59.567Z","updated_at":"2025-02-25T14:49:33.046Z","phase":"Phase 2","brief_title":"Tecemotide (L-BLP25) in Rectal Cancer","source_id_and_acronym":"NCT01507103 - SPRINT","lead_sponsor":"Merck KGaA, Darmstadt, Germany","biomarkers":" MSI • CD8 • IFNG • MLH1 • MSH6 • MUC1 • MSH2 • CEACAM5 • ISG20","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI • CD8 • IFNG • MLH1 • MSH6 • MUC1 • MSH2 • CEACAM5 • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • cyclophosphamide • Stimuvax (tecemotide) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 124","initiation":"Initiation: 02/01/2012","start_date":" 02/01/2012","primary_txt":" Primary completion: 06/01/2014","primary_completion_date":" 06/01/2014","study_txt":" Completion: 06/01/2014","study_completion_date":" 06/01/2014","last_update_posted":"2017-01-13"}]